{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:28:53Z","timestamp":1790260133607,"version":"4.1.0"},"reference-count":56,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,27]]},"DOI":"10.18632\/oncotarget.5793","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"34774-34787","source":"Crossref","is-referenced-by-count":69,"title":["Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases"],"prefix":"10.18632","volume":"6","author":[{"given":"Valerio","family":"Leoni","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gatta","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Palladini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ranieri","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Dall\u2019Ora","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grosso","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Alviano","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonsi","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Nanni","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier-Luigi","family":"Lollini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Campadelli-Fiume","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Barry","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Bell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrmicro3140","article-title":"New viruses for cancer therapy: meeting clinical needs","volume":"12","author":"Cattaneo","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Guthrie","year":"2015","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Gillespie","year":"2009","journal-title":"Mol Ther"},{"key":"6","article-title":"Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients","author":"Breitbach","year":"2014","journal-title":"Mol Ther"},{"key":"7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Dispenzieri","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/rmv.691","article-title":"Rethinking herpes simplex virus: the way to oncolytic agents","volume":"21","author":"Menotti","year":"2011","journal-title":"Rev Med Virol"},{"key":"10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Coffin","year":"2003","journal-title":"Gene Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1158\/0008-5472.CAN-07-0674","article-title":"Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses","volume":"67","author":"Martuza","year":"2007","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Rabkin","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"13","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1128\/JVI.06998-11","article-title":"Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12","volume":"86","author":"Whitley","year":"2012","journal-title":"J Virol"},{"key":"14","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1073\/pnas.0601258103","article-title":"Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor","volume":"103","author":"Roizman","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"15","doi-asserted-by":"crossref","first-page":"15124","DOI":"10.1073\/pnas.232588699","article-title":"Engineered herpes simplex virus 1 is dependent on IL13Ralpha2 receptor for cell entry and independent of glycoprotein D receptor interaction","volume":"99","author":"Roizman","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"16","first-page":"10153","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"20","author":"Campadelli-Fiume","year":"2008","journal-title":"J Virol"},{"key":"17","volume-title":"The 31st International Herpesvirus Workshop","author":"Campadelli-Fiume","year":"2006"},{"key":"18","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.4161\/cc.8.18.9368","article-title":"Oncolytic herpes virus retargeted to HER-2","volume":"8","author":"Nanni","year":"2009","journal-title":"Cell Cycle"},{"key":"19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/mt.2012.22","article-title":"Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma","volume":"20","author":"Malatesta","year":"2012","journal-title":"Mol Ther"},{"key":"20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/cgt.2012.62","article-title":"Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice","volume":"19","author":"Malatesta","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1073\/pnas.0812268106","article-title":"Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells","volume":"106","author":"Campadelli-Fiume","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"22","doi-asserted-by":"crossref","first-page":"e1003155","DOI":"10.1371\/journal.ppat.1003155","article-title":"Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus","volume":"9","author":"Lollini","year":"2013","journal-title":"PLoS Pathog"},{"key":"23","first-page":"2306","article-title":"Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype","volume":"62","author":"Zhang","year":"2002","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/cgt.2008.83","article-title":"Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice","volume":"16","author":"Tanabe","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"25","first-page":"757","article-title":"Oncolytic herpes simplex virus treatment of metastatic breast cancer","volume":"40","author":"Liu","year":"2012","journal-title":"Int J Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","article-title":"Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver","volume":"17","author":"Fong","year":"2006","journal-title":"Hum Gene Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/mt.2008.240","article-title":"A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer","volume":"17","author":"Kemeny","year":"2009","journal-title":"Mol Ther"},{"key":"28","first-page":"4089","article-title":"Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)","volume":"27","author":"Tanabe","year":"2009","journal-title":"J Clin Oncol (ASCO Meeting Abstract)"},{"key":"29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coviro.2015.06.005","article-title":"From virotherapy to oncolytic immunotherapy: where are we now?","volume":"13","author":"Coffin","year":"2015","journal-title":"Curr Opin Virol"},{"key":"30","first-page":"380","article-title":"The utility of cells as vehicles for oncolytic virus therapies","volume":"10","author":"Peng","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/gt.2008.45","article-title":"Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth","volume":"15","author":"Russell","year":"2008","journal-title":"Gene Ther"},{"key":"32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/mt.2009.194","article-title":"Cell carriers for oncolytic viruses: Fed Ex for cancer therapy","volume":"17","author":"Vile","year":"2009","journal-title":"Mol Ther"},{"key":"33","first-page":"1523","article-title":"Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer","volume":"5","author":"Molnar-Kimber","year":"1999","journal-title":"Clin Cancer Res"},{"key":"34","article-title":"Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells","author":"Nettelbeck","year":"2015","journal-title":"Int J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/mt.2014.118","article-title":"Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus","volume":"22","author":"Vile","year":"2014","journal-title":"Mol Ther"},{"key":"36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/mp200649g","article-title":"Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth","volume":"9","author":"Hsieh","year":"2012","journal-title":"Mol Pharm"},{"key":"37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2013-09-528851","article-title":"Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"38","first-page":"dju090","article-title":"Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy","volume":"106","author":"Shah","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/cgt.2010.53","article-title":"Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer","volume":"18","author":"Nishiyama","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cytogfr.2010.02.004","article-title":"Directing systemic oncolytic viral delivery to tumors via carrier cells","volume":"21","author":"Chiocca","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"41","doi-asserted-by":"crossref","first-page":"14243","DOI":"10.1074\/jbc.M609350200","article-title":"Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts","volume":"282","author":"Perbellini","year":"2007","journal-title":"J Biol Chem"},{"key":"42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","article-title":"Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal\/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)","volume":"15","author":"Gimble","year":"2013","journal-title":"Cytotherapy"},{"key":"43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/01.tp.0000173794.72151.88","article-title":"Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp","volume":"80","author":"Bagnara","year":"2005","journal-title":"Transplantation"},{"key":"44","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1128\/JVI.72.12.9992-10002.1998","article-title":"The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells","volume":"72","author":"Campadelli-Fiume","year":"1998","journal-title":"J Virol"},{"key":"45","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/annonc\/mdt036","article-title":"Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab","volume":"24","author":"Shapiro","year":"2013","journal-title":"Annals of Oncology: ESMO"},{"key":"46","volume-title":"U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) ed","author":"Office of New Drugs C, FDA","year":"2005"},{"key":"47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-11-20","article-title":"Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer","volume":"11","author":"Peng","year":"2013","journal-title":"J Transl Med"},{"key":"48","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/stem.430","article-title":"A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke","volume":"28","author":"Bang","year":"2010","journal-title":"Stem Cells"},{"key":"49","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/bcr3602","article-title":"Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2","volume":"16","author":"Nanni","year":"2014","journal-title":"Breast cancer research"},{"key":"50","article-title":"The Evolving Landscape of HER2 Targeting in Breast Cancer","author":"Krop","year":"2015","journal-title":"JAMA oncology"},{"key":"51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1073\/pnas.1423008112","article-title":"MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"52","doi-asserted-by":"crossref","first-page":"e39626","DOI":"10.1371\/journal.pone.0039626","article-title":"Multiorgan metastasis of human HER-2+ breast cancer in Rag2-\/-;Il2rg-\/- mice and treatment with PI3K inhibitor","volume":"7","author":"Lollini","year":"2012","journal-title":"PLoS One"},{"key":"53","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/JVI.29.3.1149-1158.1979","article-title":"Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity","volume":"29","author":"Spear","year":"1979","journal-title":"J Virol"},{"key":"54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/IAI.35.1.363-367.1982","article-title":"Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies","volume":"35","author":"Woodie","year":"1982","journal-title":"Infect Immun"},{"key":"55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejca.2009.11.018","article-title":"High metastatic efficiency of human sarcoma cells in Rag2\/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy","volume":"46","author":"Lollini","year":"2010","journal-title":"Eur J Cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s12015-012-9406-3","article-title":"Human genome-specific real-time PCR method for sensitive detection and reproducible quantitation of human cells in mice","volume":"8","author":"Wu","year":"2012","journal-title":"Stem Cell Rev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:43:00Z","timestamp":1594827780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,27]]},"references-count":56,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2015,10,27]]}},"alternative-id":["5793","26430966"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5793","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,27]]}}}